Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems, Inc. announced its financial results for the first quarter of 2026, reporting total revenue of $25.0 million, an increase from $19.8 million in Q1 2025. Revenue from the HEPZATO KIT™ reached $23.3 million, up from $18.0 million in the year-ago quarter.
QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025 HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025 CHE